In Real Time
Introducing CYTALUX™, the latest advancement in Intraoperative Molecular Imaging that illuminates ovarian cancer in real time.
CYTALUX™ is indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
In clinical trials, CYTALUX detected additional ovarian cancer which would have been left behind.
With CYTALUX, additional lesions were found in 27% of patients*
In a subgroup analysis of patients with confirmed FR+ ovarian cancer who underwent interval debulking surgery, additional lesions were found in 40% of interval debulking patients**
Surgeons indicated the use of CYTALUX altered their surgical plan in 54% of their cases.***
* Women highly suspicious for or with confirmed ovarian cancer who underwent both normal and fluorescent light evaluation (Intent-to-Image set); N=134, 95% CI [19.6, 35.2]
** Phase 3 (006 Study): CYTALUX FOR FR+ OVARIAN CANCER; N=58, 95% CI [27.0, 53.4]
This subgroup analysis utilized a smaller analysis set than the primary endpoint and was not adjusted to control for error, so the results are not conclusive and should be interpreted cautiously.
*** Phase 3 (006 Study): Based on a prespecified exploratory endpoint for the proportion of subjects for whom the fluorescence surgical plan was changed based on fluorescence imaging both prior to initiation of the surgical procedure and upon re-imaging of the surgical field after surgical procedure prior to closing. (N=109, 95% CI [44.3,63.7])